WG
BPMC

Winton Group’s Blueprint Medicines BPMC Stock Holding History

Winton Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,951
Closed -$2.03M – 969
2021
Q4 		$2.03M Sell
18,951
-10,951
-37% -$1.15M 0.12% 223
2021
Q3 		$3.07M Buy
29,902
+9,731
+48% +$906K 0.17% 99
2021
Q2 		$1.77M Buy
20,171
+3,233
+19% +$296K 0.1% 231
2021
Q1 		$1.65M Buy
16,938
+1,703
+11% +$170K 0.09% 208
2020
Q4 		$1.71M Sell
15,235
-16,861
-53% -$1.78M 0.12% 167
2020
Q3 		$2.98M Buy
+32,096
New +$2.47M 0.1% 332
2019
Q2 		– Sell
-3,077
Closed -$246K – 1135
2019
Q1 		$246K Buy
+3,077
New +$227K ﹤0.01% 880
2018
Q3 		– Sell
-3,170
Closed -$201K – 1019
2018
Q2 		$201K Sell
3,170
-1,693
-35% -$135K 0.01% 986
2018
Q1 		$446K Buy
+4,863
New +$419K 0.01% 828

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Winton Group's BPMC Position: Q1 2022 in Review

Winton Group sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 18,951 shares — an estimated $2.03M sold.

Winton Group first reported a position in BPMC in Q1 2018 and held it in 9 quarters. The position peaked at $3.07M in Q3 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Winton Group reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Winton Group sold 18,951 Blueprint Medicines shares in Q1 2022, an estimated $2.03M.
  • Winton Group first reported a position in Blueprint Medicines in Q1 2018 and held it in 9 quarters.
  • Winton Group's Blueprint Medicines position peaked at $3.07M in Q3 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.